KNOWLEDGE CENTER

AustinPx Capabilities Overview

Join Dave Miller, Chief Scientific Officer at AustinPx, for an overview of the company's integrated formulation development, analytical, and clinical manufacturing capabilities for complex oral drug programs. The webinar explores...

2025 AustinPx Amorphous Solid Dispersion (ASD) Workshop Recap

Go inside AustinPx’s 2025 ASD Workshop, Downstream Aspects of Amorphous Solid Dispersions. The multi-day event brought together experts from industry and academia to explore patient-centric drug product design, characterization, stability,...

Amorphous Solid Dispersions: Development Trends, Challenges and the Future

The pharmaceutical industry is pushing the boundaries of the chemical drug space in search of new and more effective compounds. However, many of these new molecules have properties that make...

KinetiSol Technology: Scale-Up Approach

Justin Keen, AustinPx Sr. VP of Operations' talk begins with a discusion on phase-appropriate process development objectives, reviewed as they relate to scale and mode changes as product development evolves...

Why KinetiSol Technology is Disrupting Spray Drying

Dave Miller, AustinPx CSO's (Chief Scientific Officer) talk begins by showcasing two case studies of commercial spray dried dispersions— replicated with KinetiSol and eliminating toxic solvents, manufacturing complexity, and improving...

Optimizing Amorphous Solid Dispersions: Overcoming Scale-Up Challenges with Next-Generation Technologies

As the number of poorly soluble molecules entering the pipeline has increased, the application of amorphous solid dispersions development has grown. With the advent of next-generation ASD technologies, like KinetiSol Technology,...

Optimizing Drug Loading in Amorphous Solid Dispersions: Maximizing Bioavailability While Minimizing Pill Burden

Amorphous solid dispersions (ASDs) have revolutionized drug delivery by enhancing the bioavailability of poorly soluble drugs. However, formulators often assume that higher drug loading in ASDs will automatically reduce pill burden...

Oral Dosage Innovation for Pediatric Drug Delivery

Pediatric drug development isn’t just about reducing adult doses. It involves unique technical, regulatory, and manufacturing challenges that require creative formulation strategies. In this webinar, experts from AustinPx and Via...

How Difficult Is it to Scale Up an Amorphous Dispersion? (Xtalks interview)

In this Xtalks interview, Dr. Justin Keen, Senior Vice President of Operations at AustinPx, explained why scale up is one of the biggest challenges in amorphous dispersion manufacturing and how KinetiSol™...

De-Risking Development: Guiding Formulation Strategy with MacroFlux to Predict Human Outcomes of KinetiSol-Processed Etravirine

KinetiSol™ Technology enables formulation of poorly soluble compounds, but predicting human performance remains a key challenge in early development. In this session, Daniel Davis, Ph.D. (Director of Business Development, AustinPx),...

Overcoming Late Stage Formulations & Manufacturing Challenges with KinetiSol Technology

In this Xtalks webinar, Dr. Dave Miller, Chief Scientific Officer at AustinPx, explores how KinetiSol™ Technology helps sponsors overcome the formulation and manufacturing hurdles that often appear late in development....

AustinPx Live Episode 1: Inside AustinPx: Live Company Overview

Originally aired on July 9th, 2025 Join us as we kick off our new AustinPx Live series with an inside look at our capabilities. AustinPx's Chief Scientific Officer, Dave Miller, will walk...

AustinPx Live Episode 2: Navigating Complexity: Tailored Analytical & Preclinical Services

Originally aired on August 19th, 2025 In the second session of AustinPx Live, Chief Scientific Officer, Dave Miller, Ph.D., will share how AustinPx designs data-driven, early-phase strategies to solve complex...

AustinPx Live Episode 3: From Molecule to Milestone: Fast-Track Formulation

Originally aired on September 25th, 2025 Watch the third session in our AustinPx Live series! Chief Scientific Officer, Dave Miller, Ph.D., will share how AustinPx approaches conventional formulation to accelerate...

AustinPx Live Episode 4: From Brick Dust to Breakthrough: The Power of Enabled Formulation

Originally aired on October 22nd, 2025 Join us for our fourth episode of AustinPx Live where Chief Scientific Officer, Dave Miller, Ph.D., will share how AustinPx uses enabling formulation strategies...

AustinPx Live Episode 5: Re-thinking ASD Development: When Your Molecule Breaks the Rules

Originally aired on January 22nd, 2026 Chief Scientific Officer, Dave Miller, Ph.D., will explore how KinetiSol™ is reshaping the design space for amorphous solid dispersions (ASDs). He’ll break down how...

AustinPx Live Episode 6: Re-thinking ASD Development: Designing for Scale from Day One

Originally aired on March 18th, 2026 Chief Technology Officer, Chris Brough, Ph.D., will lead a discussion on what it takes to successfully scale amorphous solid dispersions from early development into...

Overview: KinetiSol Technology from AustinPx

The KinetiSol™ Technology generates amorphous solid dispersions, dramatically improving the bioavailability of poorly soluble drugs. KinetiSol is a fusion-based, solvent-free process that utilizes frictional and shear energies - in a...

OutsourcedPharma Live: AustinPx Facility Tour & Capabilities Presentation

Join AustinPx's Chief Scientific Officer, Dave Miller, for a presentation focusing on our pharmaceutical manufacturing & development capabilities. Dave's presentation is followed by a virtual facility tour that will take...

AustinPx Live: Inside AustinPx: Live Company Overview (Episode 1)

We kicked off our new AustinPx Live series with Inside AustinPx: Live Company Overview, featuring Chief Scientific Officer Dave Miller, Ph.D. In this 30-minute session, Dave walked attendees through our evolution...

KinetiSol in Action: Scalable, Sustainable Amorphous Dispersion Manufacturing

See the KinetiSol Compounder in action and learn how AustinPx’s proprietary KinetiSol™ Technology supports amorphous solid dispersion (ASD) development from rapid prototyping through commercial manufacturing. This video highlights how KinetiSol’s solvent-free,...

Redefining Drug-Like Properties with KinetiSol

Christopher Lipinski’s Rule of Five (Ro5) has been used for nearly three decades to evaluate whether a compound possesses the chemical and physical properties to potentially be an orally active...

Formulation Strategies for Enabling “Undevelopable” Compounds (Poster)

Many modern drug candidates fall outside traditional guidelines like Lipinski’s Rule of Five, making them difficult to formulate with conventional technologies. This poster, presented by Dave Miller at DDC (2025)...

Tailoring Exposure for Efficacy: Next Generation PK Optimization with KinetiSol-Enabled BAE and CR Design

Many drug candidates require more than solubility enhancement to achieve optimal therapeutic performance. This presentation from Dave Miller at CRBE Summit West (2026) explores how KinetiSol™ Technology can be used...

Using KinetiSol Technology to Improve an Abandoned Prostate Cancer Medication (Galeterone)

In 2019, there were approximately 175,000 new cases of prostate cancer, contributing to 10% of male cancer-related fatalities. Galeterone, a novel prostate cancer candidate treatment, was discontinued after a Phase...

Data-Driven Development of Clofazimine: A High-Drug Load Pediatric Mini-Tablet

The development of clofazimine pediatric mini-tablets demonstrates a data-driven approach to pharmaceutical development. By leveraging predictive tools and iterative design, AustinPx transformed a formulation-challenged compound into a scalable, patient-friendly product...

Converting from a Spray-Dried Dispersion to a KinetiSol Formulation in <5 Months

A Phase 2 oral drug candidate formulated as a spray-dried dispersion faced limitations in bioavailability, pill burden, and solvent-intensive manufacturing. In less than five months, AustinPx converted the program to...

From Confidence to Concern: The Shift in Spray Drying Sentiment

By: Dave Miller, CSO, AustinPx I spent April on the move, coast to coast, conference to conference, hearing more than what was on the agenda.  I began the month on the...

What Sets AustinPx Apart: A CDMO Differentiated By Their History

By: Dave Miller, CSO, AustinPx As I’ve been out and about, attending conferences, visiting clients, and catching up with friends across the industry, one thing has become increasingly clear: AustinPx is...

DCAT Sustainability Leaders (eBook)

The first edition of The Sustainability Leaders, an eBook presented by DCAT, is now available. AustinPx is one of the sustainability leaders highlighted in this eBook, as well as the...

How Sustainable Practices in Pharma Drive Long-term Growth

Embracing sustainability is not just socially responsible but also strategically beneficial, driving long-term financial returns and strengthening relationships with patients and the broader community. At AustinPx, sustainability, innovation, and client-centricity...

How Prioritizing Sustainability Efforts Yields Long-term Growth in Drug Manufacturing

Pharmaceutical companies that invest strategically in sustainability initiatives will differentiate themselves in a competitive market. Implementing these practices ensures a robust and long-term market position, enabling stakeholders across the value...

How Difficult Is it to Scale Up an Amorphous Dispersion? (Xtalks article)

AustinPx's Justin Keen, Senior Vice President, Operations explores the scaling up of KinetiSol Technology. This innovative, solvent-free process rapidly transforms active pharmaceutical ingredients into high-quality amorphous solid dispersions, enhancing solubility and...

Trends in amorphous solid dispersion drug products approved by the U.S. FDA between 2012 and 2023

In a recent publication, the trends in ASD drug products over a 12-year period from 2012 to 2023 were analyzed. The review highlights the role of AustinPx's KinetiSol Technology, a solvent-free...

Pharma Matters Q&A: AustinPx, Talking Next-Gen Amorphous Dispersion Technology

Dave Miller, Chief Scientific Officer of AustinPx, discusses in a recent Q&A why our innovative KinetiSol Technology will revolutionize amorphous solid dispersions (ASDs) for poorly soluble APIs. Unlike traditional spray drying, KinetiSol...

Dave Miller: Pioneer in Pharmaceutical Innovation

Dave Miller, the Chief Scientific Officer (CSO) at AustinPx, is a leading figure in pharmaceutical science. His career path reflects his dedication, innovation, and commitment to excellence. From his early...

Less Mess, Less Stress, Best Expressed: A Superior Alternative To Spray Drying

In a recent article, Chris Brough, CTO of AustinPx, highlights KinetiSol Technology as a superior alternative to spray drying for amorphous solid dispersions (ASDs). Unlike spray drying, which relies on organic solvents...

Winning Strategies For Oral Dosage Form Development And Manufacturing

In a recent article, Dave Miller, CSO of AustinPx, highlights KinetiSol Technology as a superior alternative to spray drying for amorphous solid dispersions (ASDs). Failure to identify a compound’s red flags—bioavailability, stability,...

Pushing the Boundaries of Drug Development: Is Lipinski’s Rule of Five Still Relevant?

Dave Miller, Ph.D., CSO of AustinPx, challenges the continued relevance of Lipinski’s Rule of Five (Ro5) in today’s pharmaceutical landscape. As technologies like AI and in-silico modeling reshape drug discovery,...

KinetiSol Technology: A Sustainable and Efficient Revolution in Bioavailability Enhancement

CDMOs and Small Molecule Challenges: Navigating the Impact of the Inflation Reduction Act

Breaking all the Rules – Pushing the Boundaries of Lipinski’s Rule of 5

Lipinski's Rule of 5 is a guideline in drug discovery that helps predict if a molecule is likely to be orally bioavailable. It's a set of criteria based on molecular...

A Shifting CDMO Landscape: The Rise of High-Science, High-Touch

In a rapidly evolving drug development environment, capacity alone is no longer enough. In this article, AustinPx Chief Executive Officer Elizabeth Hickman unpacks how the CDMO landscape is shifting toward...

Pharma Trends and Predictions for 2025: An incoming CEO’s perspective

Elizabeth Hickman, CEO of AustinPx, outlines six key trends shaping the CDMO landscape in 2025. From the rise of GLP-1s and AI-driven molecules to growing interest in patient-centric dosage forms...

Building Resilience: CDMO Strategies for Drug Supply Chain Stability

In this article, AustinPx CEO Elizabeth Hickman highlights the critical role small-molecule CDMOs play in stabilizing today’s strained pharmaceutical supply chains. With more than 250 essential drugs in shortage, CDMOs...

Partnerships To Be Precise

Elizabeth Hickman (CEO, AustinPx) and Dave Miller (CSO, AustinPx) examine how the rise of precision medicine is reshaping the role of CDMOs. As drug developers take on increasingly complex, patient-targeted...

Sustainability in Pharma Manufacturing: Strategic Benefits of Going Green

In this piece, AustinPx's CEO, Elizabeth Hickman, explores how sustainability is becoming a strategic priority across the pharmaceutical supply chain. From renewable energy and waste reduction to IoT and blockchain-based...

Precision Without a Playbook: How Agile CDMOs Enable Personalised Drug Development

In this article, Elizabeth Hickman (CEO, AustinPx) and Dave Miller (CSO, AustinPx) discuss how as precision medicine becomes the new standard, traditional development models are falling short. This article highlights...

From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future

This article traces the evolution of API-in-capsule (AIC) technology, from its early disruption of traditional formulation through the Xcelodose® system, to its reinvention in 3P innovation’s Fill2Weight platform. The authors...

Pushing the Boundaries: Overcoming Formulation and Manufacturing Challenges (eBook w/ Pharmaceutical Technology)

Winning Strategies For Oral Dosage Form Development and Manufacturing. An eBook in partnership with Pharmaceutical Technology. Oral solid dose (OSD) formulation development must adhere to common considerations, such as project...

Collaborative Innovation in CDMOs: Interview Series with Pharmaceutical Technology (5-part)

This 5-part Pharmaceutical Technology interview series with Dave Miller, Ph.D., CSO of AustinPx, explores how the role of CDMOs is evolving from transactional service providers to true co-developers. Across the series, Dave...

How to Solve Complex Pediatric Dosing Challenges Using Tailored Solutions

In this article, Dave Miller, Ph.D. (CSO, AustinPx) explores why pediatric drug development demands more than simply reducing an adult dose. From palatability and swallowability to the precision required for...

AI Might Find the Molecule, but Delivery Decides Whether it Becomes a Medicine

In this article, AustinPx Chief Scientific Officer Dave Miller examines how the rapid expansion of AI-enabled drug discovery is reshaping the pharmaceutical pipeline. While advanced computational tools can now identify...

Solving the Problem of Insolubility: The Medicine Maker Interview Series (3-part)

In this three-part interview series with The Medicine Maker, AustinPx CEO Elizabeth Hickman and CSO Dave Miller examine the growing challenge of poorly soluble drug candidates and what it means for...

Re-Thinking the Pipeline: Development in the Age of AI

In this article, AustinPx's CEO, Elizabeth Hickman, examines how artificial intelligence is reshaping the front end of drug discovery and what that shift means for development. AI-driven tools are enabling...

From In Silico to In Vivo: Why Development Strategy Now Determines AI-Era Success

In this article, AustinPx CSO Dave Miller examines how artificial intelligence (AI) is reshaping the front end of drug discovery while exposing a growing gap between faster candidate generation and...

How CDMOs Turn “Undruggable” Into “Developable”

AustinPx CEO Elizabeth Hickman and CSO Dave Miller examine how precision medicine, AI, and advanced discovery tools are expanding what is possible in drug development while creating new formulation and...

Beyond Solvents: The Future of Sustainable Amorphous Dispersion Development

AustinPx CEO Elizabeth Hickman examines why greener amorphous solid dispersion (ASD) development requires more than simply reducing solvent use. As sustainability expectations grow, she explains how cost, risk, timelines, and...

Choosing the Best Amorphous Dispersion Path Before It Costs You

AustinPx examines why early amorphous solid dispersion (ASD) technology selection can have a major impact on cost, timelines, and long-term product value. As more oral small molecules face poor solubility,...